Home/Filings/4/0001104659-25-067427
4//SEC Filing

Cramer Pamela J. 4

Accession 0001104659-25-067427

CIK 0001649904other

Filed

Jul 10, 8:00 PM ET

Accepted

Jul 11, 4:30 PM ET

Size

17.0 KB

Accession

0001104659-25-067427

Insider Transaction Report

Form 4
Period: 2025-07-09
Cramer Pamela J.
Chief Human Resources Officer
Transactions
  • Exercise/Conversion

    Common Stock

    2025-07-09$6.80/sh+10,547$71,72029,756 total
  • Exercise/Conversion

    Common Stock

    2025-07-09$27.35/sh+5,025$137,43434,781 total
  • Sale

    Common Stock

    2025-07-09$80.00/sh3,516$281,28019,209 total
  • Exercise/Conversion

    Stock Options (Right to Buy)

    2025-07-095,02515,075 total
    Exercise: $27.35Exp: 2033-01-31Common Stock (5,025 underlying)
  • Sale

    Common Stock

    2025-07-09$75.55/sh4,225$319,21730,556 total
  • Sale

    Common Stock

    2025-07-09$76.69/sh7,831$600,56522,725 total
  • Exercise/Conversion

    Stock Options (Right to Buy)

    2025-07-0910,54717,581 total
    Exercise: $6.80Exp: 2032-02-08Common Stock (10,547 underlying)
Footnotes (5)
  • [F1]The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 16, 2024.
  • [F2]The price reported in Column 4 is a weighted average price. The securities were sold in multiple transactions at prices ranging from $75.08 to $75.98 per common stock. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  • [F3]The price reported in Column 4 is a weighted average price. The securities were sold in multiple transactions at prices ranging from $76.17 to $76.75 per common stock. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  • [F4]The stock options were granted on February 9, 2022. The options vest and become exercisable in 16 substantially equal installments upon the Reporting Person's completion of each three full months of successive service to the Issuer following the grant date.
  • [F5]The stock options were granted on February 1, 2023. The options vest and become exercisable in 16 substantially equal installments upon the Reporting Person's completion of each three full months of successive service to the Issuer following the grant date.

Issuer

RHYTHM PHARMACEUTICALS, INC.

CIK 0001649904

Entity typeother

Related Parties

1
  • filerCIK 0001873517

Filing Metadata

Form type
4
Filed
Jul 10, 8:00 PM ET
Accepted
Jul 11, 4:30 PM ET
Size
17.0 KB